Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1984-1992

  Kuhn, Sabine ^a,b   Hyde, Evelyn J ^a   Yang, Jianping ^a   Rich, Fenella J ^a   Harper, Jacquie L ^a   Kirman, Joanna R ^a,c   Ronchese, Franca ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; IMMUNE ACTIVATING AGENT; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; LIPOPOLYSACCHARIDE; NK1.1 PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG; URATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FLOW CYTOMETRY; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LUNG METASTASIS; LYMPH NODE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MONOCYTE; MOUSE; MYCOBACTERIUM SMEGMATIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOLOGICAL THERAPY; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; ESCHERICHIA COLI; FEMALE; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOCYTES; MYCOBACTERIUM SMEGMATIS; OVALBUMIN; PEPTIDE FRAGMENTS; POLY I-C; RADIATION CHIMERA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; TH1 CELLS; URIC ACID;

EID: 84881467787     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301135     Document Type: Article

References (53)

1. Stoitzner, P., L. K. Green, J. Y. Jung, K. M. Price, H. Atarea, B. Kivell, and F. Ronchese. 2008. Inefficient presentation of tumor-derived antigen by tumorinfiltrating dendritic cells. Cancer Immunol. Immunother. 57: 1665-1673.
2. Sandel, M. H., A. R. Dadabayev, A. G. Menon, H. Morreau, C. J. M. Melief, R. Offringa, S. H. van der Burg, C. M. Janssen-van Rhijn, N. G. Ensink, R. A. E. M. Tollenaar, et al. 2005. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin. Cancer Res. 11: 2576-2582.
3. Ladányi, A., J. Kiss, B. Somlai, K. Gilde, Z. Fejos, A. Mohos, I. Gaudi, and J. Tímár. 2007. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56: 1459-1469.
4. Labidi-Galy, S. I., V. Sisirak, P. Meeus, M. Gobert, I. Treilleux, A. Bajard, J.-D. Combes, J. Faget, F. Mithieux, A. Cassignol, et al. 2011. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 71: 5423-5434.
5. Sisirak, V., J. Faget, M. Gobert, N. Goutagny, N. Vey, I. Treilleux, S. Renaudineau, G. Poyet, S. I. Labidi-Galy, S. Goddard-Leon, et al. 2012. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 72: 5188-5197.
6. Gerner, M. Y., K. A. Casey, and M. F. Mescher. 2008. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J. Immunol. 181: 155-164.
7. Herber, D. L., W. Cao, Y. Nefedova, S. V. Novitskiy, S. Nagaraj, V. A. Tyurin, A. Corzo, H.-I. Cho, E. Celis, B. Lennox, et al. 2010. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16: 880-886.
8. Coley, W. B. 1910. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 3(Surg Sect): 1-48.
9. Kidner, T. B., D. L. Morton, D. J. Lee, M. Hoban, L. J. Foshag, R. R. Turner, and M. B. Faries. 2012. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J. Immunother. 35: 716-720.
10. Sylvester, R. J. 2011. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int. J. Urol. 18: 113-120.
11. Kawai, T., and S. Akira. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
12. Jo, E.-K. 2008. Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs. Curr. Opin. Infect. Dis. 21: 279-286.
13. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6: 769-776.
14. Kawarada, Y., R. Ganss, N. Garbi, T. Sacher, B. Arnold, and G. J. Hämmerling. 2001. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167: 5247-5253.
15. Currie, A. J., R. G. van der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. S. Robinson. 2008. Targeting the effector site with IFN-alphabetainducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J. Immunol. 180: 1535-1544.
16. de Bono, J. S., A. G. Dalgleish, J. Carmichael, J. Diffley, F. J. Lofts, D. Fyffe, S. Ellard, R. J. Gordon, C. J. Brindley, and T. R. Evans. 2000. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin. Cancer Res. 6: 397-405.
17. Mastini, C., P. D. Becker, M. Iezzi, C. Curcio, P. Musiani, G. Forni, F. Cavallo, and C. A. Guzmán. 2008. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. Curr. Cancer Drug Targets 8: 230-242.
18. Hamzah, J., J. G. Altin, T. Herringson, C. R. Parish, G. J. Hämmerling, H. O'Donoghue, and R. Ganss. 2009. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J. Immunol. 183: 1091-1098.
19. Kono, H., C.-J. Chen, F. Ontiveros, and K. L. Rock. 2010. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest. 120: 1939-1949.
20. Ghiringhelli, F., L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, et al. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15: 1170-1178.
21. Hu, D. E., A. M. Moore, L. L. Thomsen, and K. M. Brindle. 2004. Uric acid promotes tumor immune rejection. Cancer Res. 64: 5059-5062.
22. Lugade, A. A., J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174: 7516-7523.
23. Ataera, H., E. Hyde, K. M. Price, P. Stoitzner, and F. Ronchese. 2011. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS ONE 6: e17515.
24. Pulaski, B. A., and S. Ostrand-Rosenberg. 2001. Mouse 4T1 breast tumor model. Curr. Protoc Immunol. Chapter 20: Unit 20.22.
25. Getting, S. J., R. J. Flower, L. Parente, R. de Medicis, A. Lussier, B. A. Woliztky, M. A. Martins, and M. Perretti. 1997. Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins. J. Pharmacol. Exp. Ther. 283: 123-130.
26. Ma, J. Z., S. N. Lim, J. S. Qin, J. Yang, N. Enomoto, C. Ruedl, and F. Ronchese. 2012. Murine CD4+ T cell responses are inhibited by cytotoxic T cell-mediated killing of dendritic cells and are restored by antigen transfer. PLoS ONE 7: e37481.
27. Nierkens, S., M. H. den Brok, T. Roelofsen, J. A. L. Wagenaars, C. G. Figdor, T. J. Ruers, and G. J. Adema. 2009. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS ONE 4: e8368.
28. Wu, C.-Y., H.-Y. Yang, A. Monie, B. Ma, H.-H. Tsai, T.-C. Wu, and C.-F. Hung. 2011. Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol. Immunother. 60: 1085-1096.
29. Khoruts, A., A. Mondino, K. A. Pape, S. L. Reiner, and M. K. Jenkins. 1998. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187: 225-236.
30. Rosas, M., B. Thomas, M. Stacey, S. Gordon, and P. R. Taylor. 2010. The myeloid 7/4-antigen defines recently generated inflammatory macrophages and is synonymous with Ly-6B. J. Leukoc. Biol. 88: 169-180.
31. Rich, F. J., S. Kuhn, E. J. Hyde, J. L. Harper, F. Ronchese, and J. R. Kirman. 2012. Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis. Cancer Immunol. Immunother. 61: 2333-2342.
32. Vicari, A. P., C. Chiodoni, C. Vaure, S. Aït-Yahia, C. Dercamp, F. Matsos, O. Reynard, C. Taverne, P. Merle, M. P. Colombo, et al. 2002. Reversal of tumorinduced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196: 541-549.
33. Amos, S. M., H. J. Pegram, J. A. Westwood, L. B. John, C. Devaud, C. J. Clarke, N. P. Restifo, M. J. Smyth, P. K. Darcy, and M. H. Kershaw. 2011. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol. Immunother. 60: 671-683.
34. Langlet, C., S. Tamoutounour, S. Henri, H. Luche, L. Ardouin, C. Grégoire, B. Malissen, and M. Guilliams. 2012. CD64 expression distinguishes monocytederived and conventional dendritic cells and reveals their distinct role during intramuscular immunization. J. Immunol. 188: 1751-1760.
35. Domínguez, P. M., and C. Ardavín. 2010. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 234: 90-104.
36. Le Borgne, M., N. Etchart, A. Goubier, S. A. Lira, J. C. Sirard, N. van Rooijen, C. Caux, S. Aït-Yahia, A. Vicari, D. Kaiserlian, and B. Dubois. 2006. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24: 191-201.
37. Serbina, N. V., T. P. Salazar-Mather, C. A. Biron, W. A. Kuziel, and E. G. Pamer. 2003. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19: 59-70.
38. León, B., M. López-Bravo, and C. Ardavín. 2007. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26: 519-531.
39. Shortman, K., and S. H. Naik. 2007. Steady-state and inflammatory dendriticcell development. Nat. Rev. Immunol. 7: 19-30.
40. Greter, M., J. Helft, A. Chow, D. Hashimoto, A. Mortha, J. Agudo-Cantero, M. Bogunovic, E. L. Gautier, J. Miller, M. Leboeuf, et al. 2012. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36: 1031-1046.
41. Goldszmid, R. S., P. Caspar, A. Rivollier, S. White, A. Dzutsev, S. Hieny, B. Kelsall, G. Trinchieri, and A. Sher. 2012. NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36: 1047-1059.
42. Kerkar, S. P., R. S. Goldszmid, P. Muranski, D. Chinnasamy, Z. Yu, R. N. Reger, A. J. Leonardi, R. A. Morgan, E. Wang, F. M. Marincola, et al. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121: 4746-4757.
43. Ma, Y., S. Adjemian, S. R. Mattarollo, T. Yamazaki, L. Aymeric, H. Yang, J. P. Portela Catani, D. Hannani, H. Duret, K. Steegh, et al. 2013. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigenpresenting cells. Immunity 38: 729-741.
44. Cheong, C., I. Matos, J. H. Choi, D. B. Dandamudi, E. Shrestha, M. P. Longhi, K. L. Jeffrey, R. M. Anthony, C. Kluger, G. Nchinda, et al. 2010. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 143: 416-429.
45. Simon, A. K., E. Jones, H. Richards, K. Wright, G. Betts, A. Godkin, G. Screaton, and A. Gallimore. 2007. Regulatory T cells inhibit Fas ligandinduced innate and adaptive tumour immunity. Eur. J. Immunol. 37: 758-767.
46. Gerosa, F., B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra, and G. Trinchieri. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195: 327-333.
47. Morandi, B., L. Mortara, P. Carrega, C. Cantoni, G. Costa, R. S. Accolla, M. C. Mingari, S. Ferrini, L. Moretta, and G. Ferlazzo. 2009. NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int. Immunol. 21: 599-606.
48. Watt, S. V., D. M. Andrews, K. Takeda, M. J. Smyth, and Y. Hayakawa. 2008. IFN-gamma-dependent recruitment of mature CD27(high) NK cells to lymph nodes primed by dendritic cells. J. Immunol. 181: 5323-5330.
49. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5: 405-411.
50. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
51. Broomfield, S. A., R. G. van der Most, A. C. Prosser, S. Mahendran, M. G. Tovey, M. J. Smyth, B. W. Robinson, and A. J. Currie. 2009. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182: 5217-5224.
52. Young, S. L., M. Murphy, X. W. Zhu, P. Harnden, M. A. O'Donnell, K. James, P. M. Patel, P. J. Selby, and A. M. Jackson. 2004. Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int. J. Cancer 112: 653-660.
53. van Faassen, H., R. Dudani, L. Krishnan, and S. Sad. 2004. Prolonged antigen presentation, APC-, and CD8+ T cell turnover during mycobacterial infection: comparison with Listeria monocytogenes. J. Immunol. 172: 3491-3500.